Oncology Institute Dividend

Dividend criteria checks 0/6

Oncology Institute does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	1.7%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$0.91
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Not Many Are Piling Into The Oncology Institute, Inc. (NASDAQ:TOI) Stock Yet As It Plummets 28%

Mar 21

Is Oncology Institute (NASDAQ:TOI) A Risky Investment?

Mar 05

The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 49% But Many Are Still Ignoring The Company

Nov 10

The Oncology Institute swings to Q2 GAAP loss per share from year-ago profit

Aug 09

Shareholders Shouldn’t Be Too Comfortable With Oncology Institute's (NASDAQ:TOI) Strong Earnings

May 18

Companies Like Oncology Institute (NASDAQ:TOI) Are In A Position To Invest In Growth

Mar 16

The Oncology Institute: Capitalizing On Clinical Research Contracts

Dec 22

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if TOI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TOI's dividend payments have been increasing.

Dividend Yield vs Market

Oncology Institute Dividend Yield vs Market

How does TOI dividend yield compare to the market?
Segment	Dividend Yield
Company (TOI)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Healthcare)	1.7%
Analyst forecast in 3 Years (TOI)	n/a

Notable Dividend: Unable to evaluate TOI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TOI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate TOI's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as TOI has not reported any payouts.

Oncology Institute Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

The Oncology Institute, Inc. to Report Q1, 2024 Results on May 14, 2024

New minor risk - Market cap size

The Oncology Institute, Inc. Appoints Jordan McInerney as New Chief Development Officer

Full year 2023 earnings released: US$0.92 loss per share (vs US$0.001 profit in FY 2022)

The Oncology Institute, Inc. Provides Earnings Guidance for the Year 2024

Not Many Are Piling Into The Oncology Institute, Inc. (NASDAQ:TOI) Stock Yet As It Plummets 28%

The Oncology Institute, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Is Oncology Institute (NASDAQ:TOI) A Risky Investment?

New major risk - Share price stability

Key Executive recently bought US$127k worth of stock

New minor risk - Market cap size

Vice Chairman notifies of intention to sell stock

Vice Chairman notifies of intention to sell stock

Vice Chairman notifies of intention to sell stock

New major risk - Revenue and earnings growth

the Oncology Institute Reports Goodwill Impairment Charge for the Nine Months Ended 2023

The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 49% But Many Are Still Ignoring The Company

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.03 loss in 3Q 2022)

The Oncology Institute, Inc. to Report Q3, 2023 Results on Nov 08, 2023

The Oncology Institute, Inc. Names Jeremy Castle as Chief Operations Officer

New major risk - Revenue and earnings growth

The Oncology Institute Regains Compliance with Nasdaq Listing Requirements

The Oncology Institute, Inc. Appoints Jeremy N. Castle as Chief Operations Officer

The Oncology Institute, Inc. (NasdaqCM:TOI) announces an Equity Buyback for 2,000,000 shares, for $2 million.

Second quarter 2023 earnings released: US$0.23 loss per share (vs US$0.062 loss in 2Q 2022)

The Oncology Institute, Inc. Reaffirms Earnings Guidance for the Full Year 2023

New minor risk - Shareholder dilution

The Oncology Institute, Inc. (NasdaqCM:TOI) announces an Equity Buyback for 5,000,000 shares, for $3.75 million.

The Oncology Institute, Inc. Appoints Brad Hively as Vice Chair of the Board

The Oncology Institute, Inc. (NasdaqCM:TOI) acquired Southland Radiation Oncology Network.

the Oncology Institute, Inc. Announces Departure of Matthew Miller, M.D. as Chief Operating Officer Effective June 16, 2023

The Oncology Institute, Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$0.41 loss per share (vs US$0.21 profit in 1Q 2022)

The Oncology Institute, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2023

The Oncology Institute, Inc. Patient to Be Treated with Promising Therapy for Metastatic Ovarian Cancer

Full year 2022 earnings released: EPS: US$0.023 (vs US$0.17 loss in FY 2021)

The Oncology Institute, Inc. to Report Q4, 2022 Results on Mar 09, 2023

Chief Operating Officer recently bought US$70k worth of stock

The Oncology Institute, Inc. (NasdaqCM:TOI) acquired Practice of Dr. Labib Hashimi.

President exercised options to buy US$382k worth of stock.

The Oncology Institute, Inc. Announces Diona Simoneit to Resign as Chief Accounting Officer and Principal Accounting Officer

The Oncology Institute, Inc. (NasdaqCM:TOI) acquired The South Miami Clinic.

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

The Oncology Institute, Inc. Revises Earnings Guidance for the Year 2022

Independent Director notifies of intention to sell stock

The Oncology Institute, Inc. to Report Q3, 2022 Results on Nov 09, 2022

the Oncology Institute, Inc. Announces Executive Appointments

The Oncology Institute, Inc. (NasdaqCM:TOI) acquired BROWARD ONCOLOGY ASSOCIATES.

The Oncology Institute Enrolls Nation's First Two Patients in a Phase 3 Open-Label, Randomized Clinical Trial of Pirtobrutinib

The Oncology Institute, Inc. Appoints Two New Board Members

Second quarter 2022 earnings released: US$0.062 loss per share (vs US$0.049 profit in 2Q 2021)

The Oncology Institute, Inc. Provides Revenue Guidance for 2022

The Oncology Institute, Inc. announced that it has received $110 million in funding

The Oncology Institute swings to Q2 GAAP loss per share from year-ago profit

The Oncology Institute, Inc. (NasdaqCM:TOI) acquired Practice of Dr. Nutan Parikh.

The Oncology Institute, Inc. to Report Q2, 2022 Results on Aug 09, 2022

M33 Growth, LLC Engages in Discussion with The Oncology Institute

Havencrest Healthcare Engages in Discussion with The Oncology Institute

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

The Oncology Institute, Inc., Annual General Meeting, Jul 14, 2022

Shareholders Shouldn’t Be Too Comfortable With Oncology Institute's (NASDAQ:TOI) Strong Earnings

Founder & Chief Clinical Officer recently sold US$9.6m worth of stock

The Oncology Institute, Inc. (NasdaqCM:TOI) announces an Equity Buyback for $20 million worth of its shares.

First quarter 2022 earnings released

The Oncology Institute, Inc. Reaffirms Financial Guidance for the Year 2022

The Oncology Institute, Inc. (NasdaqCM:TOI) acquired Womens Cancer Care.

High number of new and inexperienced directors

The Oncology Institute, Inc. to Report Q1, 2022 Results on May 11, 2022

The Oncology Institute, Inc. Appoints Diona Simoneit as Principal Accounting Officer

The Oncology Institute, Inc. Appoints Mihir Shah as Chief Financial Officer

Companies Like Oncology Institute (NASDAQ:TOI) Are In A Position To Invest In Growth

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

The Oncology Institute of Hope and Innovation Announces the Promotions of Dr. Daniel Virnich to President and Dr. Matt Miller to Chief Operating Officer, Effective March 15